Dr. Abraham earned his medical degree from Harvard Medical School, following which he completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of Colorado. He previously held leadership positions at the University of Colorado, the University of Cincinnati, the University of Kentucky, and the Ohio State University. At Ohio State, Dr. Abraham held several leadership positions including an Associate Dean position, managing the College of Medicine’s non-cancer clinical and translational research portfolio. As Division Director from October 2002 until January 2019, Dr. Abraham developed one of the largest and most successful academic programs of Cardiovascular Medicine in the U.S. As a noted heart failure specialist, Dr. Abraham has been recognized as one of the “Best Doctors in America” for 20 consecutive years and has been ranked among the top 10% of physicians nationally in patient satisfaction. Dr. Abraham is recognized as an international leader in heart failure research. His research has contributed to the approval/adoption of several new therapies for heart failure, including beta-blockers, natriuretic peptides, ultrafiltration, cardiac resynchronization therapy, implantable hemodynamic monitoring devices, transvenous phrenic nerve stimulation, cardiac contractility modulation, baroreflex activation therapy, and transcatheter mitral valve repair. Dr. Abraham has authored more than 1,500 original papers, abstracts, book chapters, and review articles. He serves as series editor for the "Color Atlas and Synopsis of Cardiovascular Medicine". He has been named to the Clarivate Analytics Highly Cited Researchers list, ranking him among the top 1% most cited researchers for his subject field, and recognized as one of The World’s Most Influential Scientific Minds. In 2017, Dr. Abraham was the recipient of the American College of Cardiology Distinguished Scientist Award. In 2022, Dr. Abraham received the Pioneer Award from the Heart Failure Society of America. In addition to his clinical and scholarly activities, Dr. Abraham serves as chief medical officer at V-Wave and as a consultant to companies involved in new drug and device development for heart failure.